Alpha-2 Agonists in ADHD Treatment
This clinical review explores the pharmacological mechanisms and therapeutic applications of alpha-2 adrenergic agonists in the management of Attention-Deficit/Hyperactivity Disorder (ADHD).
Related Plans & Challenges
No public plans or challenges are linked to this source yet.
Related Blog Posts
RSD treatment includes alpha-2 agonist medications (guanfacine, clonidine) that directly target emotional reactivity, CBT adapted for ADHD, DBT distress tolerance skills, and structural strategies that reduce the behavioral consequences of rejection sensitivity.
Rejection sensitive dysphoria (RSD) and ADHD are deeply connected — up to 99% of adults with ADHD experience RSD. The ADHD brain processes rejection as a threat signal it cannot dampen, making emotional pain feel physical.
ADHD emotional dysregulation means your brain's volume dial is stuck on maximum — every frustration, excitement, or disappointment hits harder and faster than it does for most people. Here's what the science says and what actually helps.
Rejection sensitive dysphoria (RSD) is an intense emotional response to perceived rejection or criticism, commonly linked to ADHD. It's not a character flaw — it's neurological. Here's what causes it, how to recognize it, and what actually helps.